Figure 1. The major challenges of CAR-T therapy in T-cell malignancies. (A) Fratricide, in which CAR-T expressing the target antigen are “self killed” by fellow CAR-T. (B) T-cell aplasia, in which normal T cells that also express the target antigen are killed by the CAR-T in “on-target, off-tumo... More about this image found in The major challenges of CAR-T therapy in T-cell malignancies. (A) Fratrici...

Figure 2. Summary of potential strategies for overcoming fratricide, T-cell aplasia, and product contamination. G-D, gamma-delta. More about this image found in Summary of potential strategies for overcoming fratricide, T-cell aplasia, ...

Figure 1. ASH survey demographics. Depicts the characteristics of the 191 ASH member survey participants focused on classical hematologic diseases. Survey participants reported how they spent their professional time, the practice setting they worked in, as well as their geographical location. More about this image found in ASH survey demographics. Depicts the characteristics of the 191 ASH member...

Figure 2. Summary of survey results. As expected, diversity in clinical trials is low, and accessibility is difficult. Of the 4 topics included in the survey, increasing support for practicing physicians outside of academic medical centers was deemed as an opportunity for most impact. More about this image found in Summary of survey results. As expected, diversity in clinical trials is lo...

Figure 3. Geographic representation of focus group participants. A heat map displaying the United States and worldwide locations of focus group participants. The circle size increases with the number of individuals represented. AROs, academic research organizations; CROs, clinical research organ... More about this image found in Geographic representation of focus group participants. A heat map displayi...

Figure 4. Depiction of the leadership roles each focus group participant holds within their respective organization. CEO, chief executive officer; CMO, chief marketing officer; EMA, European Medicines Agency. More about this image found in Depiction of the leadership roles each focus group participant holds within...

Comparison of 2 distinct variants of t(14;18)-negative follicular lymphoma (FL) common in the pediatric age group: T-FL and PTFL. They differ in histological, immunophenotypic, and genetic features. (H&E, upper left hand corners, original magnification, x100; CD10, CD20, CD79a, and IgD, original... More about this image found in Comparison of 2 distinct variants of t(14;18)-negative follicular lymphoma ...

Figure 1. Flow diagram. The reasons for patients not enrolling in the study after screening included 2 patients withdrawing voluntarily, 4 patients not meeting the inclusion criteria (<5% blasts in the bone marrow at the screening), and 19 patients meeting the exclusion criteria (including he... More about this image found in Flow diagram. The reasons for patients not enrolling in the study after sc...

Figure 2. DOR, RFS, and OS. (A-B) Kaplan-Meier estimates the DOR, with censoring patients at subsequent allogeneic stem cell transplant (A) and without censoring (B). (C) Kaplan-Meier estimate of RFS by investigator assessment, with patients censored at subsequent allogeneic stem cell transplant... More about this image found in DOR, RFS, and OS. (A-B) Kaplan-Meier estimates the DOR, with censoring pat...

Figure 1. Mean voruciclib plasma concentration–time profiles after single-dose administration on day 1. More about this image found in Mean voruciclib plasma concentration–time profiles after single-dose admini...

Figure 2. Gene set enrichment analyses (GSEA) from patients with AML after voruciclib treatment. RNA-seq was performed on PBMCs from 6 patients with AML treated with 100 to 200 mg voruciclib. Normalized gene counts were compiled from bulk RNA-seq analysis and processed using GSEA to identify NES... More about this image found in Gene set enrichment analyses (GSEA) from patients with AML after voruciclib...